Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK investigational adjuvanted HPV vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK's investigational adjuvanted HPV vaccine is a 9-valent recombinant biologic vaccine candidate developed to prevent infections and associated clinical diseases caused by human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The vaccine is formulated with GSK's proprietary AS04 adjuvant system, which combines aluminum hydroxide with 3-O-desacyl-4'-monophosphoryl lipid A (MPL), a Toll-like receptor 4 (TLR4) agonist. This adjuvant system is designed to enhance the magnitude and duration of the immune response compared to non-adjuvanted formulations. The vaccine is currently in Phase 1/2 clinical development (NCT05496231), where its safety, reactogenicity, and immunogenicity are being evaluated in healthy young women in comparison to the licensed 9-valent HPV vaccine (Gardasil 9).
- Other names
- GSK 9-valent HPV vaccineGSK9-valent HPV vaccineGSK-9-valent HPV vaccineGSK 9vHPV vaccineGSK9vHPV vaccineGSK-9vHPV vaccine
02
Targets
TLR4 (Toll-like receptor 4)HPV11 L1HPV16 (Human papillomavirus type 16)HPV18 L1HPV31 L1HPV33 L1HPV45 L1HPV52 L1 (Human papillomavirus type 52 major capsid protein L1)HPV58 L1 (Human papillomavirus type 58 major capsid protein L1)HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)
Beyond the preview
Go deeper on GSK investigational adjuvanted HPV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK investigational adjuvanted HPV vaccine.